Urovant Sciences Ltd (NASDAQ:UROV) Short Interest Up 5.2% in September

Share on StockTwits

Urovant Sciences Ltd (NASDAQ:UROV) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 795,200 shares, a growth of 5.2% from the August 30th total of 755,700 shares. Based on an average daily volume of 37,200 shares, the days-to-cover ratio is presently 21.4 days. Approximately 10.9% of the shares of the stock are sold short.

NASDAQ:UROV opened at $9.46 on Friday. Urovant Sciences has a 12 month low of $4.05 and a 12 month high of $14.49. The stock has a 50 day moving average of $9.53 and a two-hundred day moving average of $8.54. The company has a current ratio of 6.20, a quick ratio of 6.20 and a debt-to-equity ratio of 0.29. The firm has a market cap of $284.59 million and a P/E ratio of -2.14.

Urovant Sciences (NASDAQ:UROV) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.94) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.02). On average, research analysts forecast that Urovant Sciences will post -4.02 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. Marshall Wace North America L.P. purchased a new stake in Urovant Sciences during the 1st quarter worth approximately $49,000. Sio Capital Management LLC increased its stake in Urovant Sciences by 2.3% during the 2nd quarter. Sio Capital Management LLC now owns 220,042 shares of the company’s stock worth $1,741,000 after buying an additional 5,000 shares in the last quarter. Northern Trust Corp increased its stake in Urovant Sciences by 55.8% during the 2nd quarter. Northern Trust Corp now owns 17,164 shares of the company’s stock worth $136,000 after buying an additional 6,144 shares in the last quarter. Vanguard Group Inc. increased its stake in Urovant Sciences by 7.3% during the 2nd quarter. Vanguard Group Inc. now owns 131,487 shares of the company’s stock worth $1,040,000 after buying an additional 9,000 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Urovant Sciences during the 1st quarter worth approximately $325,000. Institutional investors own 24.10% of the company’s stock.

Several research firms have commented on UROV. ValuEngine upgraded Urovant Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and set a $28.00 price objective on shares of Urovant Sciences in a research note on Monday, September 9th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $21.63.

Urovant Sciences Company Profile

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Further Reading: Short Selling Stocks and Day Traders

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.